Here, we report that CRISPR guide RNAs (gRNAs) with a 5 ′ -triphosphate group (5 ′ -ppp gRNAs) produced via in vitro transcription trigger RNA-sensing innate immune responses in human and murine cells, leading to cytotoxicity. 5 ′ -ppp gRNAs in the cytosol are recognized by DDX58, which in turn activates type I interferon responses, causing up to ∼80% cell death. We show that the triphosphate group can be removed by a phosphatase in vitro and that the resulting 5 ′ -hydroxyl gRNAs in complex with Cas9 or Cpf1 avoid innate immune responses and can achieve targeted mutagenesis at a frequency of 95% in primary human CD4 + T cells. These results are in line with previous findings that chemically synthesized sgRNAs with a 5 ′ -hydroxyl group are much more efficient than in vitro-transcribed (IVT) sgRNAs in human and other mammalian cells. The phosphatase treatment of IVT sgRNAs is a cost-effective method for making highly active sgRNAs, avoiding innate immune responses in human cells.
Clustered, regularly interspaced, short palindromic repeat (CRISPR)-CRISPR associated (Cas) nucleases, which function as an adaptive immune system in bacteria and archaea, have been repurposed for targeted genome editing in various cells and organisms (Cho et al. 2013a; . The Cas9 nuclease, the protein component in a type II CRISPR-Cas system, is complexed with two small RNAs termed a target-specific CRISPR RNA (crRNA) (∼40 nucleotides [nt] in length) and a target-independent trans-activating crRNA (tracrRNA) (∼86-nt) to form active RNAguided endonucleases (Deltcheva et al. 2011; Jinek et al. 2012) , which cleave DNA in a targeted manner, leading to site-specific genome modifications. The essential parts of the crRNA and tracrRNA are usually combined to generate a ∼100-nt single guide RNA (sgRNA). Cpf1 is another RNA-guided programmable nuclease, which is derived from a class 2 type V CRISPR-Cas system (Zetsche et al. 2015) . Unlike Cas9, Cpf1 requires only a single 42-nt crRNA to cleave target DNA.
For successful CRISPR-mediated genome editing, efficient delivery or high level expression of Cas9 or Cpf1 and a guide RNA (gRNA) is essential. Plasmids encoding Cas9 and a gRNA or in vitro-transcribed Cas9 mRNA and a gRNA can be codelivered into cells. As an alternative to these methods, preassembled Cas9 or Cpf1 ribonucleoproteins (RNPs), composed of the purified Cas9 or Cpf1 protein and a gRNA, can be also delivered into cells via microinjection (Cho et al. 2013b; Sung et al. 2014) , electroporation Hur et al. 2016) , cationic lipid-mediated transfection (Zuris et al. 2015) , or protein transduction (Ramakrishna et al. 2014) . RNPs cut target DNA immediately and are turned over rapidly in cells, which can alleviate off-target effects ) and reduce mosaicism in whole organisms (Woo et al. 2015) . Unlike plasmid transfection, RNP delivery is not associated with any risk of foreign DNA integration into the host genome ) and cannot trigger cyclic GMP-AMP synthase (cGAS) activation, an innate immune system in mammalian cells that protects against foreign DNA (Sun et al. 2013 ). This advantage of RNP delivery over plasmid transfection has made Cas9, Cpf1, and Base Editor RNPs broadly useful for biomedical research and biotechnology (Woo et al. 2015; Dever et al. 2016; Kim et al. 2017a,c; Liang et al. 2017) . gRNAs in RNP complexes are typically transcribed in vitro using phage RNA polymerases such as T7 and SP6 polymerases. These in vitro-transcribed (IVT) gRNAs contain a triphosphate group at the 5 ′ terminus, which can induce a type I interferon-mediated immune response in various cell types (Kim et al. 2004; Pichlmair et al. 2006) . The nascent 5 ′ -triphosphate moiety in such an RNA molecule is recognized as part of a non-self RNA derived from viral infection. Immune sensing of non-self nucleic acids by innate immune systems leads to the induction of the type I interferons (IFNs), which in turn activate genes that encode antiviral effector proteins such as DDX58 (DExD/H-box helicase 58, also known as RIG-I), OAS2 (2 ′ -5 ′ -oligoadenylate synthetase), and PKR (dsRNA-dependent protein kinase) (Schlee and Hartmann 2016) .
Here, we investigate whether the 5 ′ -triphosphate moiety in IVT gRNAs indeed triggers the RNA-sensing innate immune response in human cells, leading to cell death, and show how to avoid this problem. The Cas9 RNP up-regulated IFNB1 mRNA levels by ∼1000-fold and protein levels by ∼200-fold (Fig. 1B,C 
RNA-sensing immune response to CRISPR-RNA via DDX58
Cytosolic 5 ′ -triphosphorylated RNAs, the main ligand for the DDX58 receptor, can function as an indicator of viral infection (Pichlmair et al. 2006; Rehwinkel et al. 2010) . Hence, we hypothesized that DDX58 might be involved as the immune sensor responsible for detection of IVT gRNAs. To verify this, we first generated DDX58 knockout (KO) cell lines using a DDX58-specific sgRNA and Cas9 ( Fig. 2A) . We chose two KO clones with out-offrame indel mutations. mRNA levels of IFNB1, DDX58, and OAS2
were not changed in these DDX58 KO cells transfected with 5 ′ -ppp-gRNAs ( Fig. 2B-D) . Furthermore, IFN-mediated cytotoxicity associated with 5 ′ -ppp-gRNAs was not detectably induced in these cells (Fig. 2E) , suggesting that DDX58 is responsible for the innate immune response to IVT gRNAs with the 5 ′ triphosphate moiety.
Type I interferon response induced by crRNA in Cpf1 RNPs
Next, we investigated whether Cpf1 crRNAs can also activate innate immune responses in human cells. We prepared a DNMT1-specific Acidaminococcus sp. Cpf1 (AsCpf1) crRNA via chemical synthesis or in vitro transcription using T7 polymerase (Fig. 3A) . IFNB1, DDX58, and OAS2 mRNA levels were up-regulated by the 5 ′ -ppp crRNA but not by the 5 ′ -OH crRNA prepared by chemical synthesis or by treatment of the in vitro transcript with CIP ( Fig.  3B-D) . Activation of these IFN-mediated immune responses by the 5 ′ -ppp crRNA was abrogated in DDX58 KO cells (Fig. 3E-G) . Mutation frequencies associated with treatment with RNPs containing the 5 ′ -ppp crRNA or the 5 ′ -OH crRNA were comparable, showing that the cleavage activity of Cpf1 was not affected by the 5 ′ -triphosphate group of the crRNA (Fig. 3H) .
Cytotoxicity induced by 5 ′ -ppp sgRNAs in primary human T cells
Genome editing in primary human T cells has been tested in clinics for treating cancer and human immunodeficiency virus type 1 (HIV-1) infection. We investigated whether 5 ′ -triphosphate sgRNAs trigger innate immune responses in primary human T cells, causing cytotoxicity. We isolated primary CD4 + T cells from healthy volunteers (n = 3) and transfected a Cas9 RNP specific to the CCR5 gene, which encodes an essential coreceptor of HIV-1, into these cells via electroporation. We measured adenosine triphosphate (ATP) levels to monitor cell viability and found that the 5 ′ -ppp gRNA treatment significantly reduced cell viability ( * P < 0.05, * * P < 0.01), whereas 5 ′ -OH-sgRNA did not cause cytotoxicity (Fig. 4A) . Furthermore, 5 ′ -ppp gRNA-treated cells failed to divide after 7 d post-electroporation, whereas cells transfected with CIP-treated 5 ′ -OH sgRNA in complex with the Cas9 protein were successfully expanded (Fig. 4B) . We next investigated whether the cytotoxicity of 5 ′ -ppp sgRNA in primary CD4 + T cells was caused by RNA-sensing innate immune responses. As expected, OAS2 and DDX58 mRNA levels were up-regulated by the 5 ′ -triphophate sgRNA ( * * P < 0.01) (Fig.  4C,D) . The IFNB1 protein was also detected at day 3 post-electroporation (Fig. 4E) . The 5 ′ -OH sgRNA did not induce any detectable immune responses, compared to the mock control.
Highly efficient CCR5 knockout in human T cells using 5 ′ -OH sgRNA
We next measured mutation frequencies in primary T cells using targeted deep sequencing. Removal of the 5 ′ -triphosphate moiety from the sgRNA enhanced mutation efficiencies at the CCR5 target site in T cells. Thus, the 5 ′ -OH sgRNA induced indels with a frequency of 94 ± 0.4% and 92 ± 0.8% at day 3 and 7 post-electroporation, respectively, whereas the 5 ′ -ppp sgRNA inducled indels with a frequency of 87 ± 1% and 80 ± 1% ( * * P < 0.01) (Fig. 5A) . Importantly, 5
′ -OH sgRNA-treated cells remained mutated at the CCR5 locus with a frequency of 95 ± 1% at day 25 post-treatment (Fig. 5B) .
To confirm the removal of the CCR5 protein from the surface of CD4 + T cells as a result of CRISPR gene editing, we performed flow cytometry. At day 7 postelectroporation, 96% of cells (both mock-treated and Cas9 RNP-treated) were CD4 positive ( Fig. 5C ; Supplemental Fig. S2 ). Among these CD4 + T cells, only 3.7% of cells treated with the Cas9 RNP were CCR5-positive, whereas 24.4% of mock-treated cells were CCR5-positive, showing an 85% reduction in the fraction of CCR5-positive cells upon Cas9 RNP treatment ( Fig. 5D ; Supplemental Fig. S2 ).
Discussion
The delivery of CRISPR RNP complexes that consist of Cas9 or Cpf1 protein and guide RNA into mammalian Hur et al. 2016 ) and plant cells (Woo et al. 2015) and animal (Cho et al. 2013b; Sung et al. 2014 ) and human embryos (Ma et al. 2017 ) has been demonstrated as a promising approach for highly efficient and precise genome editing. CRISPR RNPs have been successfully delivered into retinal pigment epithelium cells (Kim et al. 2017b ), neuronal cells (Staahl et al. 2017) , and hair cells (Zuris et al. 2015) in mice, illustrating the broad potential for clinical applications. To prepare gRNAs for RNP delivery, in vitro transcription using phage RNA polymerases, such as T7 and SP6 polymerases, is the most accessible method because it is easier and more affordable than chemical synthesis for obtaining large amounts of RNA. In particular, the yield of ∼100-nt sgRNAs from chemical synthesis is very low (Hendel et al. 2015) , and thus preparation of sgRNAs in amounts sufficient for transfecting 10 7 ∼10 9 cells by this method can be cost-prohibitive. However, in vitro transcription using phage RNA polymerases generates a triphosphate moiety at the 5 ′ end of the gRNA, and the resulting 5 ′ -triphosphate single-stranded RNA (ssRNA) activates type I interferon-mediated immune responses in cells. Cytosolic ssRNAs bearing 5 ′ -triphosphates are recognized by the DDX58 receptor (Pichlmair et al. 2006; Rehwinkel et al. 2010) , but the preference of DDX58 for ssRNA ligands varies according to their concentration, sequence, length, conformation, and the level of shielding by proteins (Schlee and Hartmann 2016) , and thus the minimal requirement of a biologically relevant ssRNA ligand for DDX58 activity has remained unclear. Here, we demonstrated that in vitro-transcribed gRNAs in CRISPR-Cas9 or Cpf1 RNPs indeed trigger RNA-sensing innate immune responses and result in cell death, which can be prevented by removal of the 5 ′ -triphosphate group from the gRNA.
Human T cells can be gene-edited using CRISPR systems or other programmable nucleases for the treatment of various diseases, including cancer and acquired immune deficiency syndrome (AIDS). For example, a naturally occurring deletion in the CCR5 gene encoding an essential coreceptor of HIV confers resistance to HIV infection, providing the basis of cell therapy against HIV infection (Hendel et al. 2015; Hultquist et al. 2016; Xu et al. 2017 ).
Here, we showed that delivery of RNP complexes containing gRNAs lacking the 5 ′ -triphosphate rescued human CD4 + primary T cells from RNA-sensing innate immune responses, leading to efficient disruption of the CCR5 gene. Application of this strategy offers great promise for targeted cell therapy using CRISPR-Cas9, Cpf1, and Base Editor RNP complexes.
Methods
Preparation of recombinant Cas9 protein, Cpf1 protein, and guide RNA Recombinant Cas9 protein was purchased from ToolGen. Recombinant Cpf1 protein was prepared as described previously . Cas9 crRNAs, tracrRNAs, and sgRNAs and Cpf1 crRNAs were synthesized by in vitro transcription using T7 RNA polymerase and a template oligonucleotide (Supplemental Table  S1 ) as described previously . CIP (New England BioLabs) was used to remove the 5 ′ -triphosphate from gRNAs as follows: 10 µg of in vitro-transcribed RNA was treated with 250 units of CIP for 3 h at 37°C in the presence of 100 units of RNase inhibitor (New England BioLabs). Following CIP treatment, the RNA was cleaned up using a miRNeasy Mini kit (Qiagen). Chemically synthesized RNAs, which were purified using high-performance liquid chromatography (HPLC), were purchased from Integrated DNA Technologies (IDT).
Cell culture and transfection
HeLa (ATCC, CCL-2) cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 100 units/mL penicillin, 100 µg/mL streptomycin, 0.1 mM nonessential amino acids, and 10% fetal bovine serum (FBS). Mouse embryonic fibroblast cells were grown in DMEM with 20% fetal bovine serum. HeLa cells and MEF cells were transfected with 100 nM of purified Cas9 protein or Cpf1 protein and 300 nM of gRNA using Lipofectamine 2000 reagent (Invitrogen), as described in Zuris et al. (2015) .
Isolation of primary human CD4 + T cells
Peripheral blood was collected from healthy donors at the National Medical Center of Korea after informed consent with Institutional Review Board approval. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque solution (GE Healthcare). Using a magnetic activated cell sorting (MACS) CD4 + T cell isolation kit (Miltenyi Biotec), CD4 + T cells were purified by negative selection. Isolated CD4 + T cells were cultured in RPMI 1640 medium supplemented with 2 mM glutamine, 1% (v/v) nonessential amino acids, 1% (v/v) sodium pyruvate, 1% (v/v) HEPES, penicillin (50 U/mL), streptomycin (50 µg/mL), and 10% (v/v) FBS (medium and culture supplements from Invitrogen). Within 2 h of isolation, CD4 + T cells were activated with CD3/CD28 Dynabeads (Thermo Fisher Scientific). The CD3/CD28 beads were magnetically removed 72 h after activation, before delivery of RNPs for CCR5 knockout. For long-term expansion of CD4 + T cells, CD3/CD28 Dynabeads were added at 1:1 ratio (cell to bead) again at day 8 post-electroporation (day 11 post-initial activation) (Levine et al. 1997) .
RNP delivery into primary human CD4 + T cells
RNPs were delivered into T cells via electroporation. Bead-free activated CD4 + T cells were mixed with purified Cas9 protein and sgRNA complexes in MaxCyte buffer and transferred into an OC-100 processing assembly, followed by electroporation using a MaxCyte-STX transfection system (MaxCyte Systems) according to the manufacturer's instructions. After electroporation, cells were seeded on 96-well plates with 20 units/mL of recombinant human IL2.
Targeted deep sequencing for mutation detection
Genomic DNA was harvested with a DNeasy Blood & Tissue kit (Qiagen) after RNP transfection. The target regions were PCR-amplified using appropriate primer sets (Supplemental Table S1 ) for next-generation sequencing library construction. TruSeq HT Dual Index primers were used for labeling each sample. The resulting libraries were subjected to paired-end read sequencing using MiSeq (Illumina).
Measurement of relative mRNA levels by quantitative PCR
Transfected cells were lysed and mRNA was purified either 24 h or 3 d after transfection using a NucleoSpin RNA kit (MACHEREY-NAGEL). cDNAs were synthesized by reverse transcription using a miScript II RT kit (Qiagen) and quantified by qPCR using the primers listed in Supplemental Table S1 . The qPCR in primary were determined by flow cytometry. Error bars, SEM; n = 3. Statistical significances were calculated by t-test. ( * ) P < 0.05, ( * * ) P < 0.01, (n.s.) not significant.
human CD4
+ T cells was performed using TaqMan gene expression assays (Thermo Fisher Scientific) with the following primers: DDX58 (Hs01061436_m1), OAS2 (Hs00942643_m1), 18SrRNA (Hs03928990_g1).
ELISA
The amount of IFNB1 secreted into the growth medium was determined using a Human IFN beta ELISA kit (PBL Assay Science). The medium from RNP-transfected cells was collected at either 24 h or 3 d post-transfection. The IFNB1 concentration was measured according to the manufacturer's protocol.
Cell viability measurements
In the case of HeLa cells, 5 × 10 3 of either wild-type or DDX58 KO cells were plated in 96-well plates 1 d before RNP transfection. At day 3 after transfection, cell viability was determined by a WST-1 assay (Roche) according to the manufacturer's protocol. In the case of primary CD4 + T cells, they were plated in 96-well plates after electroporation to deliver RNPs. At day 3 and 7 after electroporation, the ATP level in the supernatants, a measure of cell viability, was determined using the CellTiter-Glo substrate (Promega).
Data access
The deep sequencing data from this study have been submitted to the NCBI Sequence Read Archive (SRA; https://www.ncbi.nlm.nih. gov/sra) under accession numbers SRP121089 and SRP129873.
